Skip to main content

03-11-2021 | Rheumatology | News | Article

News in brief

COVID-19 vaccines have ‘acceptable safety profile’ in people with antiphospholipid antibodies

Claire Barnard

medwireNews: Study findings suggest that messenger (m)RNA COVID-19 vaccines have a favorable short-term safety profile in people with antiphospholipid antibodies.

“[S]ome concerns have been raised regarding the safety of the vaccines in patients with antiphospholipid antibodies, as these antibodies have been reported to appear following both infection and vaccination and have been identified in patients with COVID-19,” write Savino Sciascia (San Giovanni Bosco Hub Hospital, Turin, Italy) and team in a correspondence to The Lancet Rheumatology.

In their cohort of 52 people with antiphospholipid syndrome and 50 people with antiphospholipid antibodies but without clinical features of the syndrome, 76% experienced at least one adverse event following any dose of an mRNA vaccine, all of which were transient and self-limiting within 10 days. Symptoms were mild in 71% of patients and moderate in 29%. The researchers say that there were “[n]o major adverse events nor thrombotic events.”

Although they acknowledge that “more data are needed, including from long-term follow-up,” Sciascia et al conclude that “mRNA COVID-19 vaccines seem to have an acceptable safety and tolerability profile in patients with antiphospholipid antibodies.”

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

3 November 2021: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Lancet Rheumatol 2021; doi:10.1016/S2665-9913(21)00320-9

See the research in context now

with trial summaries, expert opinion and congress coverage